Tert-butyl 4-(aminomethyl)-1,2,3,6-tetrahydropyridine-1-carboxylate | 1331777-58-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: Tert-butyl 4-(aminomethyl)-1,2,3,6-tetrahydropyridine-1-carboxylate
• 英文别名: tert-butyl 4-(aminomethyl)-3,6-dihydro-2H-pyridine-1-carboxylate
• CAS: 1331777-58-2
• 化学式: C₁₁H₂₀N₂O₂
• 分子量: 212.29
• InChiKey: JUNBPSANVJHLJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-azidomethyl-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 、 三苯基膦 、 水 在 水 、 Brine 、 Sodium sulfate-III 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 反应 16.0h， 以to provide 4-aminomethyl-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester的产率得到Tert-butyl 4-(aminomethyl)-1,2,3,6-tetrahydropyridine-1-carboxylate
  参考文献：
  名称：

  Phenyl-Heteroaryl Derivatives and Methods of Use Thereof

  摘要：

  本发明提供了式（I）的苯基-杂环芳基衍生物及其药学上可接受的盐。这些化合物可用于治疗RAGE介导的疾病，如阿尔茨海默病。本发明还涉及制备式（I）的化合物及其药学上可接受的盐的方法，包括这种化合物的制药组合物，以及使用这种化合物和/或制药组合物治疗RAGE介导的疾病。

  公开号：

  US20130197007A1

文献信息

• [EN] PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS DE PHÉNYL-HÉTÉROARYLE ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：TRANSTECH PHARMA INC

  公开号：WO2011103091A1

  公开（公告）日：2011-08-25

  The present invention provides phenyl-heteroaryl derivatives of Formula (I) and pharmaceutically acceptable salts thereof. These compounds are useful in the treatment of RAGE-mediated diseases such as Alzheimer's Disease. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use of such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.

  本发明提供了式（I）的苯基-杂环芳基衍生物及其药学上可接受的盐。这些化合物在治疗RAGE介导的疾病，如阿尔茨海默病方面是有用的。本发明还涉及制备式（I）化合物及其药学上可接受的盐的方法，包括含有这些化合物的药物组合物，以及在治疗RAGE介导的疾病中使用这些化合物和/或药物组合物的用途。
• [EN] METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE MÉTALLO-BÊTA-LACTAMASE ET LEURS MÉTHODES D'UTILISATION
  申请人：MERCK SHARP & DOHME

  公开号：WO2019018186A1

  公开（公告）日：2019-01-24

  The present invention relates to metallo-β-lactamase inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-β-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more β-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.

  本发明涉及具有以下结构的金属β-内酰胺酶抑制剂化合物的药物学可接受的盐，其中Z、RA、X1、X2和R1如本文所定义。本发明还涉及包含本发明的金属β-内酰胺酶抑制剂化合物或其药学上可接受的盐以及药学上可接受的载体的组合物，可选地与β-内酰胺类抗生素和/或β-内酰胺酶抑制剂结合。该发明还涉及治疗细菌感染的方法，包括向患者投予本发明化合物的治疗有效量，结合治疗有效量的一种或多种β-内酰胺类抗生素，可选地结合一种或多种β-内酰胺酶抑制剂化合物。本发明的化合物在克服抗生素耐药性的方法中具有用处。
• PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF
  申请人：Gohimukkula Devi R.

  公开号：US20110230458A1

  公开（公告）日：2011-09-22

  The present invention provides phenyl-heteroaryl derivatives of Formula (I) and pharmaceutically acceptable salts thereof These compounds are useful in the treatment of RAGE-mediated diseases such as Alzheimer's Disease. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use of such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.

  本发明提供了式（I）的苯基-杂环取代衍生物及其药学上可接受的盐。这些化合物在治疗RAGE介导的疾病，如阿尔茨海默病中是有用的。本发明还涉及制备式（I）化合物及其药学上可接受的盐的方法，包括这些化合物的制药组合物，以及在治疗RAGE介导的疾病时使用这些化合物和/或制药组合物。
• Phenyl-heteroaryl derivatives and methods of use thereof
  申请人：TransTech Pharma, LLC

  公开号：US09045461B2

  公开（公告）日：2015-06-02

  The present invention provides phenyl-heteroaryl derivatives of Formula (I) and pharmaceutically acceptable salts thereof These compounds are useful in the treatment of RAGE-mediated diseases. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use of such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.

  本发明提供了式（I）的苯基杂环衍生物及其药学上可接受的盐。这些化合物在治疗RAGE介导的疾病方面是有用的。本发明还涉及制备式（I）化合物及其药学上可接受的盐的方法，包括这些化合物的制药组合物以及在治疗RAGE介导的疾病方面使用这些化合物和/或制药组合物的用途。
• Metallo-beta-lactamase inhibitors and methods of use thereof
  申请人：Merck Sharp & Dohme Corp.

  公开号：US11207312B2

  公开（公告）日：2021-12-28

  The present invention relates to metallo-β-lactamase inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-β-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more β-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.

  本发明涉及式（I）的金属-β-内酰胺酶抑制剂化合物及其药学上可接受的盐，其中 Z、RA、X1、X2 和 R1 如本文所定义。本发明还涉及组合物，该组合物包含本发明的金属-β-内酰胺酶抑制剂化合物或其药学上可接受的盐，以及药学上可接受的载体，可选择与β-内酰胺抗生素和/或β-内酰胺酶抑制剂结合使用。本发明进一步涉及治疗细菌感染的方法，包括向患者施用治疗有效量的本发明化合物，与治疗有效量的一种或多种β-内酰胺类抗生素联合使用，也可选择与一种或多种β-内酰胺酶抑制剂化合物联合使用。本发明的化合物在本文所述的克服抗生素耐药性的方法中是有用的。